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1. Chemistry 
 
Melting points were determined on a Boetius PMHK apparatus and were not corrected. IR spectra were 
taken on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal. 1H and 13C NMR spectra were recorded 
on a Varian Gemini-200 spectrometer (at 200 and 50 MHz, respectively), and a Bruker Ultrashield 
Advance III spectrometer (at 500 and 125 MHz, respectively) in the indicated solvent (vide infra) using 
TMS as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants (J) 
in Hz. ESI–MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent Technologies 
1200 Series instrument equipped with Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 1.8 μm) column and 
DAD detector (190-450 nm) in combination with a 6210 Time-of-Flight LC/MS instrument in positive ion 
mode. The samples were dissolved in pure H2O (HPLC grade). The selected values were as follows: 
capillary voltage 4 kV; gas temperature 350 °C; drying gas 12 L min-1; nebulizer pressure 45 psig; 
fragmentator voltage: 70 V. Lobar LichroPrep Si 60 (40-63 μm) or LichroPrep RP-18 columns coupled to a 
Waters RI 401 detector were used for preparative column chromatography. Mass spectral analyses were 
done using electrospray ionization in positive ion mode on a Surveyor separations module coupled to a 
ThermoFinnigan TSQ AM triple quadrupole mass spectrometer. 
  
HPLC purity determination 
Compounds 2-5, 8-15 and 19-23 were analyzed for purity (HPLC) using a Waters 1525 HPLC dual pump 
system equipped with an Alltech Select degasser system and dual λ 2487 UV-VIS detector and using an 
Agilent 1200 HPLC system equipped with a Quat pump (G1311B), an injector (G1329B) 1260 ALS, TCC 
1260 (G1316A) and a detector 1260 DAD VL+ (G1315C). HPLC analysis was performed using two of 
several different methods:  
Method A: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 150mm, 1.8 µ, 
S.N. USWKY01594). Compounds were dissolved in water. The final concentrations were ~ 1 mg/mL, and 
the injection volume was 3.0 µL for compounds 2 and 20 and 4.0 µL for compounds 19 and 21-23. The 
eluent was made from the following solvents: 0.2% formic acid in water (A) and methanol (B). 
Wavelength = 254 nm. 
Method B: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 150mm, 1.8 µ, 
S.N. USWKY01594). Compounds were dissolved in water. The final concentrations were ~ 1 mg/mL, and 
the injection volume was 1.0 µL for compounds 2 and 20 and 4.0 µL for compounds 19 and 21-23. The 
eluent was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). 
Wavelength = 254 nm. 
Method C: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 150mm, 1.8 µ, 
S.N. USWKY01594). Compounds were dissolved in methanol. The final concentrations were ~ 1 mg/mL, 
and the injection volume was 0.5 µL for compounds 9, 10 and 14, 1 µL for compounds 4 and 5, 2 µL for 
compounds 8, 12 and 13 and 3 µL for compounds 3, 11, 15 and 16. The eluent was made from the 
following solvents: water (A) and methanol (B). Wavelength = 239 nm (4, 12, 14), 253 nm (5, 8-10), 328 
nm (13), 338 nm (11), 341 nm (3, 15 and 16). 
Method D: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 150mm, 1.8 µ, 
S.N. USWKY01594). Compounds were dissolved in methanol. The final concentrations were ~ 1 mg/mL, 
and the injection volume was 0.5 µL for compounds 4, 5, 9, 10, 13 and 14, and 1 µL for compounds 3, 8, 
11, 12, 15 and 16. The eluent was made from the following solvents: water (A) and acetonitrile (B). 
Wavelength = 239 nm (4, 5, 8-10 and 12-14), 338 nm (11), 341 nm (3, 15 and 16). 
All compounds were > 95% pure.  
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Synthesis 
 
General procedure for the preparation of 1,7-bis(alkylamino)-4,10-diazachrysenes  
171 and an excess of the appropriate amine were dissolved in NMP in a MW cuvette under argon. The 
reaction mixture was subjected to MW irradiation using Biotage  Initiator 2.5 apparatus for 6 h at 180 
ºC. The cooled reaction mixture was poured onto ice-water. The obtained precipitate was filtered, 
washed with water, and dried under reduced pressure. 
 
General procedure for the preparation of 1,7-bis(alkylamino)-4,10-diazachrysene hydrochlorides 
The appropriate base was suspended in 40% HCl in dry MeOH, and the reaction mixture was vigorously 
stirred for 1 h at r.t. The solvent was then removed under reduced pressure, and the remaining solid 
was suspended in dry EtOH. The EtOH was removed under reduced pressure, and the same procedure 
with EtOH was repeated two more times. Upon drying at 40 ºC under reduced pressure, the desired 
product was obtained. 
 
General procedure for the preparation of alkylaminonaphthyridines.   
An appropriate chloronaphthyridine and the excess of appropriate amine were dissolved in NMP in a 
MW cuvette under argon. The reaction mixture was subjected to MW irradiation using Biotage  Initiator 
2.5 apparatus for 2 hours at 180 ºC. The excess of amine and NMP were removed under reduced 
pressure using Kugelrohr device. The crude product was purified by column chromatography (dry flash, 
SiO2, eluent DCM 100%, DCM/MeOH, gradient 9:1→ 1:9, MeOH 100%, MeOH/NH4OH gradient 99:1 → 
8:2), unless specified otherwise. 
 
N-(4-Morpholin-4-ylbutyl)-N'-(2-morpholin-4-ylethyl)quino[8,7-h]quinoline-1,7-diamine 
tetrahydrochloride 2. 
Compound 18 (24 mg, 0.06 mmol) and excess of (4-morpholin-4-ylbutyl)amine1 
(91 mg, 0.58 mmol) were dissolved in NMP (0.7 mL) in a MW cuvette under argon. The reaction mixture 
was subjected to MW irradiation using Biotage Initiator 2.5 apparatus for 5 h at 180 ºC. The cooled 
reaction mixture was poured onto ice-water. The obtained precipitate was filtered, washed with water, 
and dried under reduced pressure. The crude product was purified by column chromatography (dry 
flash, SiO2, eluent CH2Cl2/MeOH gradient 8:2 → 1:9, 100% MeOH). The product was suspended in 40% 
HCl in dry MeOH, and the reaction mixture was vigorously stirred for 1 hour at r.t. The solvent was then 
removed under reduced pressure, and the remaining solid was suspended in dry EtOH. The EtOH was 
removed under reduced pressure, and the same procedure with EtOH was repeated two more times. 
Upon drying at 40 ºC under reduced pressure, the desired product was obtained. The yield was 22 mg 
(56 %). 2: yellow powder, mp > 280 °C. IR (ATR): 3426s, 2926w, 2726w, 2608w, 1624s, 1571m, 1497w, 
1440w, 1347w, 1266w, 1226w, 1101w, 1048w, 744w, 608w, 559w, 532w, 501w, 456w, 424w, 404w cm-
1. 1H NMR (500 MHz, CD3OD + CDCl3, δ): 9.15-9.00 (m, 2H), 8.53-8.65 (m, 2H), 8.20 (d, J = 9.2, 1H),  8.12 
(d, J = 9.4, 1H), 6.75-6.60 (m, 2H), 3.85-3.77 (m, 4H), 3.77-3.70 (m, 4H), 3.55-3.48 (m, 2H), 3.47-3.40 (m, 
2H), 2.83 (t, J = 6.4, 2H), 2.62 (ps, 4H), 2.51 (bs, 4H), 2.48-2.42 (m, 2H), 1.90-1.78 (m, 2H), 1.76-1.63 (m, 
2H). 13C NMR (125 MHz, CD3OD + CDCl3, δ): 150.74, 150.42, 148.83, 148.75, 144.73, 130.77, 120.65, 
120.31, 118.40, 117.92, 116.28, 116.22, 99.77, 99.60, 66.21, 65.98, 57.96, 55.84, 52.94, 52.79, 42.27, 
38.70, 25.68, 23.19. HRMS: m/z 515.31264 corresponds to molecular formula C30H38N6O2H
+ (error in 
ppm -0.50), 258.16023 corresponds to molecular formula C30H38N6O2H2
2+ (error in ppm +0.55), 
172.44248 corresponds to molecular formula C30H38N6O2H3
3+ (error in ppm +1.91). HPLC purity: method 
A, using gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A 
→ 90% A, flow rate 0.5 mL/min, RT 2.231, area 97.87 %; method B, using gradient protocol  0 - 2 min 
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90% A, 2 - 7 min 90% A → 0% A, 7 - 9 min 0% A, 9 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 
2.158, are 100 %. 
 
N,N'-Bis[2-(morpholin-4-yl)ethyl]-1,5-naphthyridine-4,8-diamine 3. 
General procedure given above was followed using 7 (10.00 mg, 0.05 mmol), 2-(morpholin-4-
yl)ethanamine (0.27 mL, 2.05 mmol) and NMP (0.7 mL). The crude product was purified by crystalisation 
from methanol. The yield was 14 mg (71%). 3: white powder, mp 174-177 °C. IR (ATR): 3379m, 2965m, 
2921m, 2871w, 2844w, 2812m, 1582s, 1553s, 1476w, 1457m, 1397w, 1374w, 1337m, 1295w, 1273m, 
1232m, 1144m, 1115s, 1083w, 1067w, 1031w, 978w, 947w, 918w, 859w, 815w, 767w, 665w, 629w, 
559w, 499w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.34 (d, J = 5.2, 2H), 6.86 (bs, 2H), 6.48 (d, J = 5.2, 2H), 
3.76 (t, J = 4.6, 8H), 3.45-3.35 (m, 4H), 2.74 (t, J =6.4, 4H ), 2,54 (bs, 8H). 13C NMR (125 MHz, CDCl3, δ ): 
150.21, 147.91, 133.69, 100.18, 66.95, 56.81, 53.50, 39.17. HRMS: m/z 387.24979 corresponds to 
molecular formula C20H30N6O2H
+ (error in ppm -1.32), 194.12945 corresponds to molecular formula 
C20H30N6O2H2
2+ (error in ppm +3.40). HPLC purity: method C, gradient protocol 0 - 3 min 90% A, 3 - 9 min 
90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, flow rate 0.5 mL/min, RT 0.755, area 
95.45%; method D, gradient protocol  0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 16 
min 0% A → 90% A, flow rate 0.5 mL/min, RT 0.722, area 100%. 
 
N,N'-Bis[4-(diethylamino)-1-methylbutyl]-1,5-naphthyridine-4,8-diamine 4. 
General procedure given above was followed using 7 (10 mg, 0.053 mmol), N,N-diethylpentane-1,4-
diamine (0.30 mL, 1.5 mmol) and NMP (0.6 mL). The yield was 12 mg (51%). 4: light yellow film. IR (ATR): 
3367m, 3055w, 2967s, 2931s, 2870m, 2800m, 1674w, 1636w, 1574s, 1545s, 1458m, 1379m, 1353m, 
1293m, 1241m, 1216m, 1172m, 1154m, 1089m, 991w, 918w, 815m, 722w, 675w, 632w, 548m cm-1. 1H 
NMR (500 MHz, CD3OD, δ): 8.23 (d, J = 5.5, 2H), 6.63 (d, J = 5.5, 2H), 3.80-3.75 (m, 2H), 2.57-2.48 (m, 
12H), 1.69-1.59 (m, 8H), 1.32 (d, J = 6.5, 6H), 1.01 (t, J = 7.2, 12H). 13C NMR (125 MHz, CD3OD, δ): 149.80, 
147.30, 133.32, 100.08, 52.11, 46.19, 34.13, 22.29, 19.24, 9.71. HRMS: m/z 443.38495 corresponds to 
molecular formula C26H46N6H+ (error in ppm -1.63). HPLC purity: method C, gradient protocol 0 - 2 min 
90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 
3.047, area 97.30% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 
0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.926, area 98.30%. 
 
N1,N1-Diethyl-N4-1,5-naphthyridin-4-ylpentane-1,4-diamine 5. 
General procedure given above was followed using 6 (10 mg, 0.060 mmol), 3-(morpholin-4-
yl)propanamine (0.30 mL, 1.5 mmol) and NMP (0.5 mL). The yield was 13 mg (78%). 5: light yellow film. 
IR (ATR): 3378m, 3069w, 2968s, 2933m, 2871m, 2803m, 1603s, 1578s, 1486m, 1454m, 1379m, 1369s, 
1293w, 1261w, 1226m, 1176m, 1134m, 1092m, 896w, 826m, 795m, 752w, 719w, 658m, 624w, 544m 
cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.73 (dd, J1 = 4, J2 = 1.5, 1H), 8.40 (d, J = 5.5, 1H), 8.14 (dd, J1 = 8.8, J2 
= 1.8, 1H), 7.65 (dd, J1 = 8.5, J2 = 4.5, 1H), 6.69 (d, J = 5.5, 1H), 3.85-3.82 (m, 1H), 2.55-2.47 (m, 6H), 1.73-
1.59 (m, 4H), 1.34 (d, J = 6.5, 3H), 1.00 (t, J = 7.2, 6H). 13C NMR (125 MHz, CD3OD, δ): 152.58, 151.97, 
148.42, 143.97, 136.86, 136.23, 126.29, 100.94, 53.70, 49.23, 47.79, 35.65, 24.07, 20.78, 11.33. HRMS: 
m/z 287.22190 corresponds to molecular formula C17H26N4H+ (error in ppm -3.91). HPLC purity: method 
C, gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 15 min 0% A → 90% 
A, flow rate 0.5 mL/min, RT 6.168, area 96.00% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 
90% A → 0% A, 7 - 10 min 0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.799, area 
95.52%. 
 
4-Chloro-1,5-naphthyridine 6. 
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Compound ZS96 (162 mg, 1.11 mmol) was dissolved in POCl3 (2.5 mL), and the reaction mixture was 
stirred at 115 °C for 15 min in a closed vessel. The solution was poured onto ice-water and K2CO3 was 
added until pH = 10. The product was extracted with CH2Cl2 and the combined organic layers were dried 
over anh. Na2SO4. Dichloromethane was removed under reduced pressure, and the mixture was purified 
by column chromatography (dry flash, SiO2, eluent Hex/EtOAc, gradient 8:2→ 1:9, 100% EtOAc). The 
yield was 154 mg (84%). 6: white powder, mp 100 °C. IR (ATR): 3068w, 3028s, 2926w, 2827w, 2658w, 
1730w, 1582w, 1552w, 1485s, 1376w, 1356w, 1283m, 1250w, 1194w, 1133w, 1102w, 1072w, 1029w, 
983m, 863m, 824m, 790m, 658m, 637w, 568w cm-1. 1H NMR (500 MHz, CDCl3, δ): 9.64-9.62 (m, 1H), 
9.36 (d, J = 5.8, 1H), 9.26-9.23 (m, 1H), 8.51 (d, J = 5.5, 1H), 8.47 (dd, J1 = 8.7, J2 = 4.8, 1H). 13C NMR (125 
MHz, CDCl3, δ): 155.16, 154.04, 150.27, 140.20, 139.70, 139.46, 132.29, 129.98. HRMS: m/z 165.02076 
corresponds to molecular formula C8H5N2ClH
+ (error in ppm -3.88). 
 
2,2-Dimethyl-5-[(pyridin-3-ylamino)methylidene]-1,3-dioxane-4,6-dione ZS95.  
Meldrum’s acid (1.50 g, 10.4 mmol) was dissolved in EtOH (24 mL), and 3-aminopyridine (0.89 g, 9.5 
mmol) was added to the solution followed by triethyl orthoformate (1.40 g, 9.45 mmol). The mixture 
was stirred with heating at 100 ºC until ethanol evaporated. The solid residue was dissolved in a minimal 
amount of hot EtOH, charcoal was added, and the suspension was heated to boiling and quickly filtered 
through warm Cellite. The quickly formed crystals were filtered and washed with a small amount of 
EtOH. The yield was 1.53 g (65%). ZS95: off-white powder, mp 135 °C.  IR (ATR): 3236w, 3206w, 3074w, 
2993w, 2946w, 1726m, 1686s, 1619s, 1579m, 1480m, 1454w, 1413s, 1380m, 1325m, 1284m, 1262m, 
1222m, 1144w, 1022w, 1000w, 936w, 847w, 822w, 803m, 778w, 726w, 704w, 654w, 604w, 507w cm-1. 
1H NMR (500 MHz, CDCl3, δ): 11.26 (d, J = 13.4, H-N, exchangeable with D2O), 8.64 (d, J = 14.2, 1H), 8.63-
8.61 (m, 1H), 8.56-8.54 (m, 1H), 7.66-7.62 (m, 1H), 7.43-7.39 (m, 1H), 1.77 (s, 6H). 13C NMR (125 MHz, 
CDCl3, δ): 165.41, 163.04, 152.74, 147.86, 140.51, 134.55, 124.68, 124.25, 105.44, 88.71, 27.06. HRMS: 
m/z 249.08686 corresponds to molecular formula C12H12N2O4H
+ (error in ppm -0.48).  
 
1,5-Naphthyridin-4-ol ZS96.  
The solution of ZS95 (100 mg, 0.403 mmol) in diphenyl ether (3.0 mL) was refluxed for 50 min on a 
Bunsen burner. The mixture was then cooled to room temperature and formed precipitate was then 
filtered and washed with hexane. The crude product was dried, and purified by sublimation at 210 °C 
and 20 mbar. The yield was 40 mg (68%). ZS96: white crystals, slowly sublimes at >200 °C. IR (ATR): 
3012m, 2925s, 2855s, 2077w, 1975w, 1623s, 1583m, 1559m, 1502s, 1461m, 1421m, 1328w, 1192w, 
1137w, 1073w, 977w, 885w, 818w, 779w, 724w, 682w, 590w, 546w, 481w cm-1. 1H NMR (500 MHz, 
CDCl3 + d-TFA, δ): 9.15 (dd, J1 = 8.8, J2 = 1.2, 1H), 9.12-9.10 (m, 1H), 8.51 (d, J = 7.4), 8.41 (dd, J1 = 8.9, J2 = 
5.4, 1H), 7.19 (d, J = 7.4, 1H). 13C NMR (125 MHz, CDCl3 + d-TFA, δ): 173.25, 147.30, 144.98, 142.03, 
131.98, 131.43, 121.01, 116.06. HRMS: m/z 147.05496 corresponds to molecular formula C8H6N2OH
+ 
(error in ppm -2.22). 
 
4,8-Dichloro-1,5-naphthyridine 7.  
The solution of ZS153 (2.00 g, 6.814 mmol) in diphenyl ether (200 mL) was refluxed for 25 min with 
Bunsen burner. The mixture was then quickly cooled to room temperature and poured into hexane (300 
mL). The formed precipitate was filtered, suspended in ethyl acetate, and then filtered again. Crude 
product was dried in vacuum desiccator, suspended in POCl3 (70 mL), and the reaction mixture was 
stirred at 120 °C for 4 h in closed vessel. Solution was poured onto ice-water (150 mL) and K2CO3 was 
added until pH=10. The product was extracted with CH2Cl2 (3×50 mL) and the combined organic layers 
were dried over anhydrous sodium sulfate. Dichloromethane was removed under reduced pressure, and 
the obtained residue was crudely purified by column chromatography (dry flash, SiO2, eluent Hex/EtOAc, 
gradient 1:1→ 1:9, 100% EtOAc). The crude product (446.2 mg) was dissolved in 48% hydrobromic acid 
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(45 mL), and the solution was stirred at 120 °C for 48 hours in a closed vessel. The solvent was then 
removed under reduced pressure, and the solid residue (701.4 mg) was dissolved in POCl3 (28 mL). The 
mixture was stirred at 120 °C for 4 hours in a closed vessel. The solution was poured onto ice-water (50 
mL) and K2CO3 was added until pH=10. The product was extracted with CH2Cl2 (3×30 mL) and the 
combined organic layers were dried over anhydrous sodium sulfate. Dichloromethane was removed 
under reduced pressure, and the obtained residue was crudely purified by column chromatography (dry 
flash, SiO2, eluent Hex/EtOAc, gradient 1:1→ 1:9, 100% EtOAc). The yield was 312 mg (23%). 7: white 
powder, mp 270 °C. IR (ATR): 3067m, 3027m, 1724w, 1579w, 1467s, 1378m, 1263m, 1190w, 1046w, 
865m, 758m, 614w cm-1. 1H NMR (500 MHz, CDCl3 + d-TFA, δ): 9.32 (d, J = 5, 2H), 8.25 (d, J = 5, 2H). 
13C 
NMR (125 MHz, CDCl3 + d-TFA, δ): 150.43, 148.18, 137.60, 128.42. HRMS: m/z 198.98195 corresponds to 
molecular formula C8H4N2Cl2H
+ (error in ppm -2.42). 
 
3-Nitropyridine-4-ol ZS107.  
Synthesis according to established procedures.2 ZS107: light yellow crystals, mp 234-235 °C. IR (ATR): 
3158w, 3071m, 2810w, 2168w, 2110w, 1967w, 1946w, 1815w, 1643s, 1612s, 1544m, 1519w, 1497s, 
1340s, 1242w, 1157w, 1096w, 1021w, 972w, 902w, 836m, 770w, 664w, 589w, 563w, 516w cm-1. 1H 
NMR (500 MHz, d-DMSO, δ): 12.28 (bs, H-O, exchangeable with D2O), 8.78 (d, J = 1.5, 1H), 7.76 (dd, J1 = 
7.5, J2 = 1.5, 1H), 6.47 (d, J = 7.5, 1H), 3.37 (bs, 1H). 
13C NMR (125 MHz, d-DMSO, δ): 168.36, 139.74, 
138.38, 137.84, 122.39. HRMS: m/z 281.05184 corresponds to molecular formula [2C5H4N2O3 + H]
+ (error 
in ppm +0.62), 141.02942 corresponds to molecular formula C5H4N2O3H
+ (error in ppm -0.36).  
 
4-Methoxy-3-nitropyridine ZS151. 
Potassium carbonate (4.16 g, 0.030 mol) and CH3I (1.72 mL, 0.028 mol) were added to a solution of 
ZS107 (3.50 g, 0.025 mol) in acetone (130 mL) and the mixture was stirred at 40 °C. After 3 h methanol 
was added (200 mL), the obtained precipitate was filtered, washed with methanol, and methanol was 
then removed under reduced pressure. The solid residue was purified by column chromatography (dry 
flash, SiO2, eluent MeOH 100%, MeOH/NH4OH gradient 9:1 → 3:7). The yield was 3.08 g (80%). ZS151: 
yellow powder, mp 81-82 °C. IR (ATR): 3456s, 3088w, 3061w, 2920w, 2851w, 1661m, 1595m, 1504w, 
1394w, 1364w, 1316m, 1205w, 930w, 833w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.92 (d, J = 2.3, 1H), 
7.79 (dd, J1 = 7.6, J2 = 2.3, 1H), 6.66 (d, J = 7.6, 1H), 3.87 (s, 3H). 
13C NMR (125 MHz, CD3OD, δ): 171.06, 
165.02, 145.35, 143.84, 124.49, 45.04. HRMS: m/z 177.02655 corresponds to molecular formula 
C6H6N2O3Na
+ (error in ppm -2.88), 155.04484 corresponds to molecular formula C6H6N2O3H
+ (error in 
ppm -1.82).  
 
4-Methoxypyridine-3-amine ZS152.  
Synthesis according to established procedures.3 ZS152: brown powder, mp 88-89 °C. IR (ATR): 3365s, 
1638m, 1556s, 1534m, 1501m, 1435w, 1393w, 1364w, 1316w, 1248w, 1191w, 986w, 833w, 721w cm-1. 
1H NMR (500 MHz, CD3OD, δ): 7.44 (dd, J1 = 6.9, J2 = 2, 1H), 7.31 (d, J = 2.3, 1H), 6.33 (d, J = 6.9, 1H), 3.75 
(s, 3H). 13C NMR (125 MHz, CD3OD, δ): 171.16, 140.64, 137.79, 123.76, 112.98, 44.89. HRMS: m/z 
249.13390 corresponds to molecular formula 2C6H8N2OH
+ (error in ppm -2.80), 125.07043 corresponds 
to molecular formula C6H8N2OH
+ (error in ppm -4.07). 
 
Diethyl {[(4-methoxypyridin-3-yl)amino]methylidene}propanedioate ZS153. 
Diethyl ethoxymethylenemalonate (3.84 mL, 0.019 mol) was added dropwise to a solution of 4-
methoxypyridine-3-amine (2.41 g, 0.019 mol) in ethanol (70 mL). The mixture was heated to 100 °C and 
stirred in an open flask until ethanol evaporated. The solid residue was purified by column 
chromatography (dry flash, SiO2, eluent EtOAc/MeOH gradient 9:1 → 1:1). The yield was 4.83 g (85%). 
ZS153: light brown powder, mp 91-92 °C. IR (ATR): 3578w, 3413w, 3225w, 3053w, 3002w, 2905w, 
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1698s, 1666m, 1600s, 1568s, 1447w, 1426w, 1385w, 1355w, 1306w, 1264m, 1223m, 1089m, 1020w, 
1003w, 926w, 843w, 797w, 615w, 553w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.53-8.43 (m, 1H), 8.08 (d, J 
= 2, 1H), 7.67 (dd, J1 = 7.2, J2 = 1.8, 1H), 6.44 (d, J = 7.1, 1H), 4.35-4.13 (m, 4H), 3.86 (s, 3H), 1.42-1.23 (m, 
6H). 13C NMR (125 MHz, CD3OD, δ): 171.28, 169.50, 168.75, 167.74, 150.35, 141.70, 131.77, 127.91, 
115.64, 95.71, 61.53, 45.16, 14.87. HRMS: m/z 589.24793 corresponds to molecular formula 
[2C14H18N2O5 + H]
+ (error in ppm -4.22), 317.11044 corresponds to molecular formula C14H18N2O5Na
+ 
(error in ppm -1.11), 295.12967 corresponds to molecular formula C14H18N2O5H
+ (error in ppm +2.80). 
 
N-(3-Morpholin-4-ylpropyl)-1,5-naphthyridin-4-amine 8. 
General procedure given above was followed using 6 (10 mg, 0.061 mmol), 3-(morpholin-4-
yl)propanamine (0.30 mL, 2.0 mmol) and NMP (0.5 mL). The yield was 15 mg (91%). 8: light yellow film. 
IR (ATR): 3384m, 3237m, 3070m, 3005w, 2951m, 2856m, 2813m, 1699w, 1650w, 1603s, 1580s, 1533s, 
1486m, 1459m, 1390m, 1359s, 1306m, 1270w, 1220m, 1168w, 1137m, 1116s, 1071w, 1031w, 988w, 
862m, 827m, 795m, 768w, 723w, 680w, 657w, 613w, 581w, 548w cm-1. 1H NMR (500 MHz, CD3OD, δ): 
8.74 (dd, J1 = 4.25, J2 = 1.2, 1H), 8.39 (d, J = 5.5, 1H), 8.14 (dd, J1 = 8.8, J2 = 4.2, 1H), 7.66 (dd, J1 = 8.8, J2 = 
4.2, 1H), 6.66 (d, J = 5.5, 1H), 3.78 (t, J = 4.8, 4H), 3.48 (t, J = 6.5, 2H), 2.56 (t, J = 6.8, 2H), 2.51 (bs, 4H), 
1.95 (quint, J = 6.5, 2H). 13C NMR (125 MHz, CD3OD, δ): 153.06, 152.18, 148.48, 143.50, 136.40, 136.34, 
126.38, 100.60, 67.89, 58.36, 55.03, 42.68, 25.97. HRMS: m/z 273.17014 corresponds to molecular 
formula C15H20N4OH+ (error in ppm -3.11). HPLC purity: method C, gradient protocol 0 - 3 min 90% A, 3 - 
9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 15 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.002, area 
95.76% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 0% A, 10 – 12 
min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.903, area 98.02%. 
 
N,N-Diethyl-N'-1,5-naphthyridin-4-ylpropane-1,3-diamine 9. 
General procedure given above was followed using 6 (21 mg, 0.13 mmol), N,N-diethylpropane-1,3-
diamine (0.30 mL, 1.9 mmol) and NMP (0.5 mL). The yield was 20 mg (59%). 9: light yellow film. IR (ATR): 
3664w, 3390s, 3254s, 3068m, 2968s, 2934s, 2872s, 2809s, 2570w, 2425w, 1916w, 1604s, 1579s, 1532s, 
1468s, 1383s, 1360s, 1293m, 1267m, 1219s, 1172m, 1126s, 1071m, 1019w, 980w, 940w, 884w, 827s, 
794s, 723m, 684w, 657m, 615m, 545m cm-1. 1H NMR (200 MHz, CD3OD, δ): 8.71 (dd, J1 = 4, J2 = 1.2, 1H), 
8.38 (d, J = 5.6, 1H), 8.12 (dd, J1 = 9, J2 = 1.7, 1H), 7.62 (dd, J1 = 8.6, J2 = 4.2, 1H), 6.63 (d, J = 5.6, 1H), 3.42 
(t, J = 6.7, 2H), 2.66-2.48 (m, 6H), 1.89 (quint, J = 6.7, 2H), 1.04 (t, J = 7.3, 6H). 13C NMR (50 MHz, CD3OD, 
δ): 152.64, 152.41, 148.36, 143.72, 136.58, 126.14, 100.54, 51.66, 47.78, 42.04, 26.35, 11.40. HRMS: m/z 
259.19099 corresponds to molecular formula C15H22N4H+ (error in ppm -2.82). HPLC purity: method C, 
gradient protocol 0 - 1 min 90% A, 1 - 6 min 90% A → 0% A, 6 - 8 min 0% A, flow rate 0.5 mL/min, RT 
2.222, area 98.30% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 
0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.814, area 99.49%. 
 
1-Morpholin-4-yl-3-(1,5-naphthyridin-4-ylamino)propan-2-ol 10. 
General procedure given above was followed using 6 (30 mg, 0.18 mmol), 1-amino-3-morpholin-4-
ylpropan-2-ol1 (0.30 mL, 1.9 mmol) and NMP (0.6 mL). The yield was 28 mg (54%). 10: light yellow film. 
IR (ATR): 3854w, 3749w, 3673w, 3649w, 3384s, 3220m, 2953m, 2858m, 2815s, 2693m, 2572w, 1698w, 
1652w, 1605s, 1581s, 1535s, 1490m, 1456m, 1361s, 1298m, 1272m, 1221m, 1116s, 1072m, 1037w, 
1007m, 910w, 891w, 865m, 827m, 795m, 732m, 701w, 657m, 631m, 567m cm-1. 1H NMR (500 MHz, 
CD3OD, δ): 8.73-8.71 (m, 1H), 8.40 (d, J = 5.5, 1H), 8.15-8.11 (m, 1H), 7.64 (dd, J1 = 8.5, J2 = 4, 1H), 6.70 
(d, J = 5.5, 1H), 4.10 (quint, J = 6, 1H), 3.74 (t, J = 4.8, 4H), 3.47 (ddd, J1= 32.8, J2 = 13.5, J3 = 5, 2H), 2.56-
2.52 (m, 6H). 13C NMR (125 MHz, CD3OD, δ): 152.84, 152.51, 148.51, 143.78, 136.72, 136.35, 126.28, 
100.90, 67.98, 67.57, 64.44, 55.61, 48.46. HRMS: m/z 289.16586 corresponds to molecular formula 
C15H20N4O2H+ (error in ppm -0.15). HPLC purity: method C, gradient protocol 0 - 1 min 90% A, 1 - 6 min 
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90% A → 0% A, 6 - 8 min 0% A, flow rate 0.5 mL/min, RT 2.326, area 97.49% ; method D, gradient 
protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 0% A, 10 – 12 min 0% A → 90% A, flow 
rate 0.5 mL/min, RT 6.804, area 100%. 
 
N-(7C-hloroquinolin-4-yl)-N'-(1,5-naphthyridin-4-yl)butane-1,4-diamine  11. 
General procedure given above was followed using 6 (10 mg, 0.06 mmol), N-(7-chloroquinolin-4-
yl)butane-1,4-diamine (36 mg, 0.14 mmol) and NMP (0.7 mL). The cooled reaction mixture was poured 
onto ice-water. The obtained precipitate was filtered, washed with water, and dried under reduced 
pressure. The crude product was purified by column chromatography (dry flash, SiO2, eluent MeOH, 
MeOH/NH4OH gradient 99:1 → 8:2). The yield was 9 mg (38%). 11: colorless film. IR (ATR): 3235m, 
3065w, 2953w, 2868w, 1664w, 1607w, 1580s, 1533m, 1490w, 1448w, 1358w, 1335w, 1309w, 1275w, 
1204w, 1136w, 898w, 848w, 823w, 801w, 760w, 572w, 464w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.68 
(dd, J1 = 4.1, J2 = 1.6, 1H), 8.35 (d, J = 5.5, 1H), 8.29 (d, J = 5.8, 1H), 8.11 (dd, J1 = 8.5, J2 = 1.6, 1H), 8.05 (d, 
J = 9.1, 1H), 7.73 (d, J = 2.0, 1H), 7.66-7.60 (m, 1H), 7.37 (dd, J1 = 9, J2 = 2, 1H), 6.65 (d, J = 5.6, 1H), 6.53 
(d, J = 5.8, 1H), 3.52-3.43 (m, 4H), 1.97-1.88 (m, 4H). 13C NMR (125 MHz, CD3OD, δ): 151.26, 151.19, 
150.35, 150.31, 148.30, 146.88, 142.45, 136.31, 135.11, 134.61, 127.38, 125.19, 124.74, 121.50, 117.03, 
99.55, 98.60, 42.55, 41.98, 26.19, 25.92. HRMS: m/z 378.14721 corresponds to molecular formula 
C21H20ClN5H
+ (error in ppm -2.09), 189.57781 corresponds to molecular formula C21H20ClN5H2
2+ (error in 
ppm +0.89). HPLC purity: method C, gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 
min 0% A, 12 – 16 min 0% A → 90% A, flow rate 0.5 mL/min, RT 0.995, area 99.34%; method D, gradient 
protocol  0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 16 min 0% A → 90% A, flow 
rate 0.5 mL/min, RT 0.766, area 96.95%. 
 
N,N'-Bis(3-morpholin-4-ylpropyl)-1,5-naphthyridine-4,8-diamine 12. 
General procedure given above was followed using 7 (5 mg, 0.027 mmol), 3-(morpholin-4-
yl)propanamine (0.30 mL, 2.0 mmol) and NMP (0.5 mL). The yield was 4 mg (33%). 12: light yellow film. 
IR (ATR): 3233m, 3072w, 3047w, 2949m, 2922m, 2890m, 2855m, 2819s, 2772m, 2692w, 2660w, 1700w, 
1570s, 1545s, 1468s, 1398m, 1336m, 1304m, 1265m, 1224s, 1188w, 1146m, 1114s, 1068m, 1032w, 
999w, 968w, 925w, 900w, 861m, 809m, 766m, 743m, 712m, 633m, 609w, 573w, 544m cm-1. 1H NMR 
(500 MHz, CD3OD, δ): 8.25 (d, J = 5, 2H), 6.61 (d, J = 5.5, 2H), 3.74 (t, J = 4.5, 8H), 3.42 (t, J = 6.5, 4H), 2.54 
(d, J = 7, 4H), 2.50 (bs, 8H), 1.94 (quint, J = 7, 4H). 13C NMR (125 MHz, CD3OD, δ): 150.55, 147.40, 133.35, 
99.80, 66.28, 56.45, 53.41, 40.69, 24.77. HRMS: m/z 415.28160 corresponds to molecular formula 
C22H34N6O2H+ (error in ppm -2.35). HPLC purity: method C, gradient protocol 0 - 3 min 90% A, 3 - 9 min 
90% A → 0% A, 9 - 12 min 0% A, 12 – 15 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.227, area 
95.55% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 0% A, 10 – 12 
min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.812, area 97.48%. 
 
N,N'-Bis[3-(diethylamino)propyl]-1,5-naphthyridine-4,8-diamine 13. 
General procedure given above was followed using 7 (6 mg, 0.031 mmol), N,N-diethylpropane-1,3-
diamine (0.30 mL, 1.9 mmol) and NMP (0.5 mL). The yield was 5 mg (41%). 13: light yellow film. IR (ATR): 
3383m, 2967m, 2930m, 2871w, 2805m, 1550s, 1468m, 1348m, 1294w, 1220m, 1170w, 1138w, 1072w, 
815m, 729w, 632w, 537w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.25 (d, J = 5, 2H), 6.61 (d, J = 5.5, 2H), 
3.38 (t, J = 6.8, 4H), 2.66-2.60 (m, 4H), 2.58 (q, J = 7.5, 8H), 1.93-1.88 (m, 4H), 1.05 (t, J = 7.2, 12H). 13C 
NMR (125 MHz, CD3OD, δ): 152.08, 149.03, 134.91, 101.50, 51.61, 47.93, 42.12, 26.72, 11.51. HRMS: 
m/z 387.32269 corresponds to molecular formula C22H38N6H+ (error in ppm -0.98). HPLC purity: method 
C, gradient protocol 0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 10 min 0% A, 10 – 12 min 0% A → 90% 
A, flow rate 0.5 mL/min, RT 6.977, area 99.30% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 
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90% A → 0% A, 7 - 10 min 0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.826, area 
99.81%. 
 
1,1'-[1,5-Naphthyridine-4,8-diyldi(imino)]bis(3-morpholin-4-ylpropan-2-ol) 14. 
General procedure given above was followed using 7 (11 mg, 0.056 mmol), 1-amino-3-morpholin-4-
ylpropan-2-ol1 (257 mg, 1.47 mmol) and NMP (0.8 mL). The yield was 17 mg (67%). 14: light yellow film. 
IR (ATR): 3386s, 2934s, 2857s, 2814s, 2691m, 1914w, 1697w, 1665w, 1572s, 1551s, 1457s, 1395m, 
1352m, 1298m, 1274m, 1222s, 1142m, 1115s, 1071m, 1038w, 1008m, 940w, 914w, 865m, 818m, 734m, 
700w, 633m, 576w cm-1. 1H NMR (500 MHz, CD3OD, δ): 8.26 (d, J = 5.5, 2H), 6.64 (d, J = 5, 2H), 4.08 
(quint, J = 5.8, 2H), 3.72 (t, J = 4.5, 8H), 3.41 (ddd, J1 = 50, J2 = 13, J3 = 5.5, 4H), 2.54-2.50 (m, 12H). 
13C 
NMR (125 MHz, CD3OD, δ): 152.19, 149.08, 135.02, 101.65, 67.99, 67.73, 64.25, 55.57, 48.41. HRMS: 
m/z 447.27104 corresponds to molecular formula C22H34N6O4H+ (error in ppm -0.88).  HPLC purity: 
method C, gradient protocol 0 - 1 min 90% A, 1 - 6 min 90% A → 0% A, 6 - 7 min 0% A, flow rate 0.5 
mL/min, RT 2.177, area 98.21% ; method D, gradient protocol  0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 
7 - 10 min 0% A, 10 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 6.775, area 99.17%. 
 
N,N'-Bis[2-(diethylamino)ethyl]-1,5-naphthyridine-4,8-diamine 15. 
General procedure given above was followed using 7 (10 mg, 0.05 mmol), N,N-diethylethane-1,3-
diamine (0.25 mL, 1.78 mmol) and NMP (0.7 mL). The yield was 8 mg (46%). 15: light yellow film. IR 
(ATR): 3378m, 2971m, 2932w, 2869w, 2806w, 1582s, 1552s, 1462m, 1383w, 1334w, 1292w, 1255w, 
1229m, 1176w, 1126w, 1068w, 974w, 808w, 746w, 593w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.31 (d, J = 
5.2, 2H), 6.89 (bs, 2H), 6.50 (d, J = 5.2, 2H), 3.46 – 3.33 (m, 4H), 2.83 (t, J = 6.6, 4H), 2.72 – 2.62 (m, 8H), 
1.09 (t, J = 7.1, 12H). 13C NMR (125 MHz, CDCl3, δ): 150.21, 147.68, 133.41, 100.18, 51.22, 47.01, 40.39, 
11.48.  HRMS: m/z 359.29188 corresponds to molecular formula C20H34N6H
+ (error in ppm +0.31), 
180.15066 corresponds to molecular formula C20H34N6H2
2+ (error in ppm +6.30). HPLC purity: method C, 
gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 16 min 0% A → 90% A, 
flow rate 0.5 mL/min, RT 1.024, area 97,81%; method D, gradient protocol  0 - 3 min 90% A, 3 - 9 min 
90% A → 0% A, 9 - 12 min 0% A, 12 – 16 min 0% A → 90% A, flow rate 0.5 mL/min, RT 0.803, area 
96.95%. 
 
N,N'-Bis[4-(morpholin-4-yl)butyl]-1,5-naphthyridine-4,8-diamine 16. 
General procedure given above was followed using 7 (10 mg, 0.05 mmol), (4-morpholin-4-
ylbutyl)amineError! Bookmark not defined. (284.3 mg, 1.80 mmol) and NMP (0.7 mL). The yield was 9 mg (46%). 
16: light yellow film. IR (ATR): 3357s, 2940m, 2864m, 2806m, 2686w, 1660w, 1632w, 1544s, 1469m, 
1396w, 1351m, 1306w , 1269w, 1249w, 1225w, 1142w, 1112m, 1066w, 1025w, 973w, 940w,911w, 
869w, 845w, 821w, 781w, 741w, 633w, 611w, 554w cm-1. 1H NMR (500 MHz, CDCl3, δ): 8.28 (d, J = 5.2, 
2H), 6.65-6.56 (m, 2H), 6.46 (d, J = 5.2, 2H), 3.72 (t, J = 4.6, 8H), 3.37-3.28 (m, 4H), 2.53-2.34 (m, 12H), 
1.85-1.74 (m, 4H), 1.70-1.60 (m, 4H). 13C NMR (125 MHz, CDCl3, δ): 150.27, 147.69, 133.53, 99.96, 66.98, 
58.41, 53.73, 42.51, 26.73, 24.17. HRMS: m/z 443.31186 corresponds to molecular formula C24H38N6O2H
+ 
(error in ppm -2.34), 222.16077 corresponds to molecular formula C24H38N6O2H2
2+ (error in ppm +3.06), 
148.44312 corresponds to molecular formula C24H38N6O2H3
3+ (error in ppm +4.28). HPLC purity: method 
C, gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 16 min 0% A → 90% 
A, flow rate 0.5 mL/min, RT 1.033, area 99.92% ; method D, gradient protocol  0 - 3 min 90% A, 3 - 9 min 
90% A → 0% A, 9 - 12 min 0% A, 12 – 16 min 0% A → 90% A, flow rate 0.5 mL/min, RT 1.027, area 
96.27%. 
 
7-Chloro-N-(2-morpholin-4-ylethyl)quino[8,7-h]quinolin-1-amine 18. 
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Compound 17 (100 mg, 0.335 mmol) and excess of 2-(morpholin-4-yl)ethanamine (420 mg, 3.22 mmol) 
were dissolved in NMP (3 mL) in MW cuvette under argon. The reaction mixture was subjected to MW 
irradiation using Biotage Initiator 2.5 apparatus for 20 min at 150 ºC. The cooled reaction mixture was 
poured onto ice-water. The obtained precipitate was filtered, washed with water, and dried under 
reduced pressure. The crude product was purified by column chromatography (dry flash, SiO2, eluent 
CH2Cl2, CH2Cl2/MeOH gradient 9:1 → 3:7). The yield was 83 mg (63%). 18: off-white powder, mp = 194-
196 °C. IC (ATR): 3382m, 2960w, 2927w, 2862w, 2826w, 1588s, 1538s, 1490w, 1455w, 1420w, 1376w, 
1333w, 1310w, 1263w, 1234w, 1201w, 1143w, 1111m, 1070w, 1037w, 1009w, 915w, 860w, 826w, 
795w, 759w cm-1.  1H NMR (500 MHz, CD3OD + CDCl3): 9.18 (d, J = 9.4, 1H ), 9.11 (d, J = 9.4, 1H), 8.83 (d, J 
= 4.8, 1H), 8.55 (d, J = 5.5, 1H), 8.29 (d, J = 9.4, 1H), 8.12 (d, J = 9.2, 1H), 7.65 (d, J = 4.8, 1H), 6.64 (d, J = 
5.5, 1H), 3.82-3.70 (m, 4H), 3.52-3.42 (m, 2H), 2.85-2.75 (m, 2H), 2.58 (bs, 4H). 13C NMR (125 MHz, 
CD3OD + CDCl3): 150.45, 149.03, 148.01, 146.01, 144.35, 142.33, 130.94, 130.67, 124.77, 127.03, 121.74, 
120.82, 120.29, 118.98, 116.79, 99.98, 66.20, 55.79, 52.79, 38.70. HRMS: m/z 393.14686 corresponds to 
molecular formula C22H21ClN4OH
+ (error in ppm -2.04), 197.07737 corresponds to molecular formula 
C22H21ClN4OH2
2+ (error in ppm -0.50). 
 
N-[3-(Diethylamino)propyl]-N'-(2-morpholin-4-ylethyl)quino[8,7-h]quinoline-1,7-diamine 
tetrahydrochloride 19. 
Compound 18 (10 mg, 0.026 mmol) and excess of N,N-diethylpropane-1,3-diamine (34 mg, 0.26 mmol) 
were dissolved in NMP (0.6 mL) in MW cuvette under argon. The reaction mixture was subjected to MW 
irradiation using Biotage Initiator 2.5 apparatus for 5 hours at 180 ºC. The cooled reaction mixture was 
poured onto ice-water. The obtained precipitate was filtered, washed with water, and dried under 
reduced pressure. The crude product was purified by column chromatography (dry flash, SiO2, eluent 
CH2Cl2, CH2Cl2/MeOH gradient 9:1 → 1:9, MeOH, MeOH/NH3 9:1). The product was suspended in 40% 
HCl in dry MeOH, and the reaction mixture was vigorously stirred for 1 h at r.t. The solvent was then 
removed under reduced pressure, and the remaining solid was suspended in dry EtOH. The EtOH was 
removed under reduced pressure, and the same procedure with EtOH was repeated two more times. 
Upon drying at 40 ºC under reduced pressure, the desired product was obtained. The yield was 7 mg 
(40%). 19: yellow powder, mp > 280 °C. IR (ATR): 3399s, 1622s, 1573s, 1504m, 1441m, 1354w, 1231w, 
1097w, 748w cm-1. 1H NMR (500 MHz, D2O): 9.03 – 8.99 (m, 4H), 8.92 (d, J = 7, 1H), 8.84 (d, J = 7.3, 1H), 
8.79 – 8.73 (m, 2H), 7.48 (d, J = 7, 1H), 7.41 (d, J = 7.3, 1H), 4.40 (t, J = 6.6, 2H), 4.29 (bs, 4H), 4.07 (t, J = 
7, 2H), 3.97 (t, J = 6.6, 2H), 3.79 (bs, 4H), 3.62 – 3.57 (m, 2H), 3.52 (q, J = 7.3, 4H), 2.56 – 2.50 (m, 2H), 
1.55 (t, J = 7.3, 6H). 13C NMR (125 MHz, D2O): 155.95, 155.86, 142.19, 141.70, 135.00, 134.83, 124.70, 
124.66, 120.99, 120.92, 120.24, 119.94, 101.10, 100.83, 63.63, 54.14, 52.13, 49.05, 47.49, 40.55, 37.42, 
22.32, 8.20. HPLC purity: method A, using gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 
12 min 0% A, 12 – 14 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.254, area 99.59 %; method B, using 
gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, 
flow rate 0.5 mL/min, RT 2.186, area 100 %. 
 
1-Morpholin-4-yl-3-({7-[(2-morpholin-4-ylethyl)amino]quino[8,7-h]quinolin-1-yl}amino)propan-2-ol 
tetrahydrochloride 20. 
Compound 18 (22 mg, 0.060 mmol) and excess of 1-amino-3-morpholin-4-ylpropan-2-olError! Bookmark not 
defined. (98 mg, 0.56 mmol) were dissolved in NMP (0.7 mL) in a MW cuvette under argon. The reaction 
mixture was subjected to MW irradiation using Biotage Initiator 2.5 apparatus for 5 hours at 180 ºC. The 
cooled reaction mixture was poured onto ice-water and K2CO3 was added to pH = 13. The product was 
extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium 
sulfate, and the solvent was removed under reduced pressure. The crude product was purified by 
column chromatography (dry flash, SiO2, eluent CH2Cl2/MeOH gradient 9:1 → 1:9, 100% MeOH). The 
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product was suspended in 40% HCl in dry MeOH, and the reaction mixture was vigorously stirred for 1 
hour at r.t. The solvent was then removed under reduced pressure, and the remaining solid was 
suspended in dry EtOH. The EtOH was removed under reduced pressure, and the same procedure with 
EtOH was repeated two more times. Upon drying at 40 ºC under reduced pressure, the desired product 
was obtained. The yield was 27 mg (73 %). 20: light brown powder, mp > 280 °C. IR (ATR): 3419s, 2932w, 
1623s, 1570m, 1499w, 1440w, 1348w, 1267w, 1229w, 1130w, 1098w, 980w, 906w, 869w, 822w, 744w, 
571w cm-1. 1H NMR (500 MHz, CD3OD + CDCl3, δ): 9.10-9.05 (m, 2H), 8.61-8.55 (m, 2H), 8.19 (d, J = 9.4, 
1H), 8.15 (d, J = 9.4 1H), 6.77 (d, J = 5.8, 1H), 6.71(d, J =5.8, 1H), 4.21-4.15 (m, 1H), 3.83-3.76 (m, 8H), 
3.73 (bs, H-O), 3.58-3.51 (m, 3H), 3.46 (dd, J1 = 13.0, J2 = 6.6, 1H), 2.83 (t, J = 6.4, 2H), 2.67-2.57 (m, 10H). 
13C NMR (125 MHz, CD3OD + CDCl3, δ): 150.94, 150.59, 148.62, 148.51, 144.38, 130.62, 130.56, 120.52, 
120.49, 118.25, 118.15, 116.23, 99.86, 99.81, 66.22, 66.19, 65.22, 62.57, 55.81, 53.57, 52.79, 47.30, 
38.74. HRMS: m/z 517.29220 corresponds to molecular formula C29H36N6O3H
+ (error in ppm +0.06), 
259.15032 corresponds to molecular formula C29H36N6O3H2
2+ (error in ppm +2.30), 173.10265 
corresponds to molecular formula C29H36N6O3H3
3+ (error in ppm +2.37). HPLC purity: method A, using 
gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, 
flow rate 0.5 mL/min, RT 2.250, area 99.17 %; method B, using gradient protocol 0 - 2 min 90% A, 2 - 7 
min 90% A → 0% A, 7 - 9 min 0% A, 9 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.161, area 100 
%. 
 
N,N'-Bis{2-[2-(dimethylamino)ethoxy]ethyl}quino[8,7-h]quinoline-1,7-diamine tetrahydrochloride 21. 
General procedure given above was followed using ZS134 (10 mg, 0.020 mmol) and 40% HCl in dry 
MeOH (1 mL). The yield was 123 mg (98 %). 21: off-white powder, mp > 280 °C. IR (ATR): 3380s, 3020m, 
1621s, 1573m, 1502m, 1476m, 1440m, 1400w, 1345w, 1314w, 1228w, 1175w, 1122m, 990w, 929w, 
826w, 748w, 568w cm-1. 1H NMR (500 MHz, D2O): 8.46 (d, J = 7.1, 2H), 8.35 (d, J = 6.2, 2H), 8.25 (d, J = 
9.2, 2H), 7.15 (d, J = 7.3, 2H), 4.01 – 3.96 (m, 4H), 3.96 – 3.90 (m, 8H), 3.43 – 3.39 (m, 4H), 2.92 (s, 12H). 
13C NMR (125 MHz, D2O):  155.76, 141.45, 134.42, 124.14, 120.68, 119.72, 115.41, 100.94, 68.07, 64.26, 
56.60, 43.17, 42.79. HRMS: m/z 491.31200 corresponds to molecular formula C28H38N6O2H
+ (error in 
ppm -1.83). HPLC purity: method A, using gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 
12 min 0% A, 12 – 14 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.273, area 98.88 %; method B, using 
gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, 
flow rate 0.5 mL/min, RT 2.206, area 100 %. 
 
N,N'-Bis(4-aminobutyl)quino[8,7-h]quinoline-1,7-diamine dihydrochloride 22. 
General procedure given above was followed using ZS136 (10 mg, 0.025 mmol) and 40% HCl in dry 
MeOH (1 mL). The yield was 11 mg (100 %). 22: yellow powder, mp > 280 °C. IR (ATR): 3477s, 3447s, 
3208s, 3026s, 1620s, 1574s, 1503m, 1472m, 1446m, 1403w, 1363w, 1320w, 1270w, 1229m, 1159w, 
1114w, 1089w, 1036w, 1007w, 929w, 905w, 827w, 779w, 749w, 700w, 572w cm-1. 1H NMR (500 MHz, 
D2O): 8.41 (d, J = 7, 2H), 8.21 (ABq, JAB = 9.3, 4H), 7.06 (d, J = 7.1, 2H), 3.73 – 3.97 (m, 4H), 3.16 – 3.11 (m, 
4H), 1.99 – 1.85 (m, 8H). 13C NMR (125 MHz, D2O): 155.42, 141.31, 134.30, 124.00, 120.58, 119.49, 
115.31, 100.67, 43.06, 39.05, 24.51, 24.27. HRMS: m/z 403.25983 corresponds to molecular formula 
C24H30N6H
+ (error in ppm -1.59). HPLC purity: method A, using gradient protocol 0 - 3 min 90% A, 3 - 9 
min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.204, area 
99.70 %; method B, using gradient protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 
12 – 14 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.176, area 99.63 %. 
 
N,N'-Bis(3-aminopropyl)quino[8,7-h]quinoline-1,7-diamine tetrahydrochloride 23. 
General procedure given above was followed using ZS138 (10 mg, 0.027 mmol) and 40% HCl in dry 
MeOH (1 mL). The yield was 134 mg (99 %). 23: yellow powder, mp > 280 °C. IR (ATR): 3394s, 3209m, 
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2993s, 1615s, 1571s, 1502m, 1476m, 1441m, 1404w, 1356w, 1317w, 1272w, 1231m, 1161w, 1113w, 
1088w, 990w, 830w, 810w, 749w, 701w, 628w, 566w 572w cm-1. 1H NMR (500 MHz, D2O): 8.41 (d, J = 7, 
2H), 8.14 (ABq, JAB = 9.3, 4H), 7.10 (d, J = 7.1, 2H), 3.83 – 3.77 (m, 4H), 3.29 – 3.23 (m, 4H), 2.31 – 2.23 
(m, 4H). 13C NMR (125 MHz, D2O): 155.64, 141.60, 134.45, 124.18, 120.71, 119.72, 115.57, 100.78, 
40.68, 37.06, 25.51. HRMS: m/z 375.22836 corresponds to molecular formula C22H26N6H
+ (error in ppm -
2.18). HPLC purity: method A, using gradient protocol 0 - 2 min 90% A, 2 - 7 min 90% A → 0% A, 7 - 9 min 
0% A, 9 – 12 min 0% A → 90% A, flow rate 0.5 mL/min, RT 2.328, area 96.26 %; method B, using gradient 
protocol 0 - 3 min 90% A, 3 - 9 min 90% A → 0% A, 9 - 12 min 0% A, 12 – 14 min 0% A → 90% A, flow rate 
0.5 mL/min, RT 2.231, area 98.47 %. 
 
N,N'-Bis{2-[2-(dimethylamino)ethoxy]ethyl}quino[8,7-h]quinoline-1,7-diamine ZS134. 
General procedure given above was followed using 17 (50 mg, 0.17 mmol), 2-(2-aminoethoxy)-N,N-
dimethylethanamine (256 mg, 1.94 mmol) and NMP (1.0 mL). The yield was 73 mg (89 %). ZS134: pale-
brown powder, mp=122 °C. IR (ATR): 3381s, 2954s, 2864s, 2824m, 2782m, 1601s, 1544s, 1460m, 1361w, 
1337m, 1251w, 1180w, 1125m, 1071w, 1036w, 959w, 831w, 810w, 760w cm-1. 1H NMR (500 MHz, TFA): 
9.04 (d, J = 9.4, 2H), 8.76 (d, J = 7.3, 2H), 8.72 (d, J = 9.4, 2H), 7.35 (d, J = 7.4, 2H), 4.30 – 4.23 (m, 4H), 
4.21 – 4.13 (m, 8H), 3.74 – 3.69 (m, 4H), 3.27 (s, 12H). 13C NMR (125 MHz, TFA): 159.33, 144.20, 137.90, 
127.90, 123.31, 122.79, 118.99, 103.49, 70.77, 66.41, 60.30, 46.12, 45.80. HRMS: m/z 491.31226 
corresponds to molecular formula C28H38N6O2H
+ (error in ppm -1.30).  
 
N,N'-Bis(4-aminobutyl)quino[8,7-h]quinoline-1,7-diamine ZS136. 
General procedure given above was followed using 17 (52 mg, 0.17 mmol), 1,4-diaminobutane (612 mg, 
6.94 mmol) and NMP (1.0 mL). The yield was 50 mg (72 %). ZS136: pale-brown powder, mp = 224 - 226 
°C. IR (ATR): 3347m, 2925m, 2854m, 1596s, 1543s, 1475m, 1433m, 1344m, 1246w, 1180w, 1119w, 
1030w, 907w, 848w, 758w, 668w cm-1. 1H NMR (500 MHz, TFA): 8.99 (d, J = 9.4, 2H), 8.74 – 8.68 (m, 4H), 
7.30 (d, J = 7.3, 2H), 3.99 (bs, 4H), 3.55 (bs, 4H), 2.25 (bs, 8H). 13C NMR (125 MHz, TFA): 159.11, 144.01, 
137.81, 127.80, 123.20, 122.57, 118.92, 103.21, 45.75, 43.15, 26.90, 26.77. HRMS: m/z 403.25996 
corresponds to molecular formula C24H30N6H
+ (error in ppm -1.27). 
 
N,N'-Bis(3-aminopropyl)quino[8,7-h]quinoline-1,7-diamine ZS138. 
General procedure given above was followed using 17 (52 mg, 0.17 mmol), 1,3-diaminopropane (513 
mg, 6.92 mmol) and NMP (1.0 mL). The yield was 64 mg (99%). ZS138: pale-brown powder, mp = 218 - 
220 °C. IR (ATR): 3288s, 2942s, 2858m, 1596s, 1542s, 1471m, 1433m, 1393w, 1345m, 1245w, 1176w, 
1125w, 956w, 920w, 856w, 801w, 754w, 547w cm-1. 1H NMR (500 MHz, TFA + D2O): 7.24 (d, J = 9.4, 2H), 
6.96 – 6.89 (m, 4H), 5.44 (d, J = 7.1, 2H), 2.22 – 2.15 (m, 4H), 1.69 – 1.63 (m, 4H), 0.74 – 0.66 (m, 4H). 13C 
NMR (125 MHz, TFA + D2O): 159.83, 145.20, 138.86, 128.82, 124.33, 123.80, 119.88, 103.92, 43.88, 
40.73, 28.77. HRMS: m/z 375.22917 corresponds to molecular formula C22H26N6H
+ (error in ppm -1.97).  
 
Synthesis of compound 7  
4,8-Dichloro-1,5-naphthyridine 7.  
The solution of ZS153 (2.00 g, 6.814 mmol) in diphenyl ether (200 mL) was refluxed for 25 min with 
Bunsen burner. The mixture was then quickly cooled to room temperature and poured into hexane (300 
mL). The formed precipitate was filtered, suspended in ethyl acetate, and then filtered again. Crude 
product was dried in vacuum desiccator, suspended in POCl3 (70 mL), and the reaction mixture was 
stirred at 120 °C for 4 h in closed vessel. Solution was poured onto ice-water (150 mL) and K2CO3 was 
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added until pH=10. The product was extracted with CH2Cl2 (3×50 mL) and the combined organic layers 
were dried over anhydrous sodium sulfate. Dichloromethane was removed under reduced pressure, and 
the obtained residue was crudely purified by column chromatography (dry flash, SiO2, eluent Hex/EtOAc, 
gradient 1:1→ 1:9, 100% EtOAc). The crude product (446.2 mg) was dissolved in 48% hydrobromic acid 
(45 mL), and the solution was stirred at 120 °C for 48 hours in a closed vessel. The solvent was then 
removed under reduced pressure, and the solid residue (701.4 mg) was dissolved in POCl3 (28 mL). The 
mixture was stirred at 120 °C for 4 hours in a closed vessel. The solution was poured onto ice-water (50 
mL) and K2CO3 was added until pH=10. The product was extracted with CH2Cl2 (3×30 mL) and the 
combined organic layers were dried over anhydrous sodium sulfate. Dichloromethane was removed 
under reduced pressure, and the obtained residue was crudely purified by column chromatography (dry 
flash, SiO2, eluent Hex/EtOAc, gradient 1:1→ 1:9, 100% EtOAc). The yield was 312 mg (23%).  
 
N
N
OEtO
O
OEt
O H
N
N
Cl
Cl O
OEt
intermedier 2
N
N
O
OH O
OEt
a) b)
   ZS153 intermedier 1
N
N
Cl
Cl
+
N
N
Cl
Cl
b)
c)
7
a) Ph
2
O/> 260 oC/25 min; b) POCl
3
/120 oC/4 h; c) 48% HBr/120 oC/48 h
N
N
Cl
Cl
x HBr
Mw = 360.86
N
N
OH
Cl
x HBr+
Mw = 261.507
crude mixture 1
crude mixture 2
hypothesized structures  
 
 
 
 
 
 
 
 
NMR spectrum of “Crude mixture 1”: 
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NMR spectrum of 7 (ZS94): 
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Naphthyridine core synthesis (compounds 6 and 7) 
 
Key intermediate 6 (Scheme S1) was obtained in analogy to previously reported procedures 
(Scheme 1).4,5 The three-component condensation product ZS95 was subsequently cyclized in boiling 
diphenyl ether and the obtained ZS96 was purified by sublimation. The procedure used by Brown6 to 
synthesize another important intermediate, dichloride 7, was modified in two key steps (Scheme 1). The 
first part of the synthesis followed Brown’s procedure. Nitration of 4-pyridone gave rise to ZS1072, 
which was then methylated to ZS151. Upon reduction of the nitro group the obtained amine ZS1523, 
was subjected to condensation with diethyl ethoxymethylenemalonate affording ZS153 in good yield 
over four steps.  Formation of the second pyridine ring, and the subsequent decarboxylation step, were 
performed by prolonged refluxing of ZS153 in concentrated hydrobromic acid, rather than using 
quinoline and vacuum-thermal decarboxylation6, which sped up and eased the synthesis. Finally, both 
key intermediates 6 and 7 were obtained after POCl3 treatment of respective hydroxy precursors 
(Scheme 1).  
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Scheme S1. The synthesis of monochloro- (6) and dichloro-naphthyridine (7). 
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2. In vitro and in vivo EBOV assays: 
 
In vitro: 
 
• Two hours prior to infection, compounds were dispensed via the HP D300 directly from 100% 
DMSO stocks into assay cell plates. DMSO was normalized in all wells to a final 1.0%. 
• Compound activity was tested in a 10-point dose response with 2-fold step dilutions starting at 
10 µM (final). Doses were repeated 4 times on a single plate (n=4).  
• Sixteen wells/plate were treated as neutral (infected) controls.  
• Additionally, 16 uninfected wells/plate were used as low signal controls.  
• Cells were infected with EBOV (Kikwit) MOI = 0.5 (HeLa). 
• Infection was stopped after 48h by fixing cells with a formalin solution. 
 
Plate Statistics for Quality Control, standard compound: 
 
Table S1. 
 
 
 
 
 
Figure S1. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo:  
 
Animals: Mice Balb/c, 10 mice per test 
 
Virus: Mouse adapted Ebolavirus (Zaire) 
Index Cell line Pathogen MOI Plate ID Date
Well 
Masking
Nuclei - 
Number, 
NC
% Infection Z' Factor
# of 
Analyzed 
Fields
EC50 
(uM)
SD
1 HeLa EBOV 0.5 AA00000913 2/3/2016 0.26% 5228 69.24 0.75 5 0.2 0.02
2 HeLa EBOV 0.5 AA00000914 2/3/2016 0.00% 5281 70.19 0.78 5 0.2 0.01
3 HeLa EBOV 0.5 AA00000915 2/4/2016 0.00% 4648 74.95 0.83 5 0.2 0.01
4 HeLa EBOV 0.5 AA00000916 2/4/2016 0.00% 4454 72.66 0.78 5 0.2 0.01
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Dose of pathogen: 1000 pfu 
Route of compound treatment: IP 
Route of pathogen infection: IP 
 
3. ADME data7  
Table S2. 
ADMET Properties Units Good Moderate Poor 
Purity % > 90   
Solubility pH 7.4 (g/mL) > 50 10 – 50 < 10 
Stability-Microsomes 
T
1/2
 (min) > 30 15 - 30 < 15 
CL
int
 (L/min/mg) < 46 46 - 92 > 92 
Stability -Plasma  % Remaining at 1 hr > 85 20 - 85 < 20 
CYP450 Inhibition 
% Inhibition at 3 M < 15 15 - 50 > 50 
IC
50
 (M) > 10 1 - 10 < 1 
MDR1-MDCKII 
P
app
 (a-b, 10
-6
cm/s) > 20 2 - 20 < 2 
Pgp Efflux Ratio < 1.5 1.5 - 2.5 > 2.5 
 
 
Permeability: 
Table S3: 2 (ZSML08) Apparent Permeability with Two Technical Replicates for Each of Three Biological 
Replicates 
 
Assay Date REP 1 REP 2 REP 1 REP 2 
7/27 PAPP A→B ± SD PAPP A→B ± SD PAPP B→A ± SD PAPP B→A ± SD 
ATENOLOL 0.39 ± 0.07 0.15 ± 0.05 0.43 ± 0.02 0.30 ± 0.01 
PRAZOSIN 27.87 ± 0.5 27.62 ± 0.48 54.02 ± 1.32 48.58 ± 1.18 
PROPRANOLOL 39.03 ± 0.73 38.26 ± 0.63 42.86 ± 1.31 41.56 ± 1.24 
2 (ZSML08) 45.82 ± 33.22 67.21 ± 40.14 55.57 ± 13.70 67.29 ± 10.20 
 
 
 
 
 
 
 
Comment [B1]: Rajini, what should be 
done about these large standard 
deviations? 
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Table S4: 2 (ZSML08) Apparent Permeability with Three Biological Replicates 
Assay Date 
8/9/2017 PAPP A→B ± SD PAPP B→A ± SD 
ATENOLOL 0.79 ± 0.15 0.59 ± 0.12 
PRAZOSIN 30.02 ± 0.56 58.87 ± 1.32 
PROPRANOLOL 37.74 ± 1.81 41.90 ± 0.81 
2 (ZSML08) 39.29 ± 25.40 43.16 ± 9.13 
 
These assays were run in the MDCK model for intestinal absorption. The standard deviation values for 
the apparent permeability constants for 2 are very large. The standards shown (atenolol, prazosin, and 
propranolol) were run on the same plate at the same time as 2, and do not display large standard 
deviation values. The technical repeats shown in Table S3 are separate analytical runs of the same three 
biological replicates that were run on the same day. Table S4 shows the data from the three biological 
replicates and one analytical run that were run on a separate day from the samples used to generate the 
data in Table S3. 
 
Even with the large stand deviation values, the apparent permeability values for 2 indicate moderate to 
high permeability. 
 
4. Fluorescence and UV-Vis spectra of binding to HSA and AGP 
 
Compound 1 
 
AGP: 
 
 
Figure S2. Changes in AGP fluorescence emission spectra upon addition of 1 (1-5 molar equivalents); 
T=298.0 K±0.1 °C, 30 mM PBS, pH=7.35. 
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Figure S3. The Stern-Volmer plot for binding of 1 to AGP. y = 1 + 81248.0 x. 
 
Ksv=(8.12±0.07)×10
4 M-1   
 
HSA: 
 
 
Figure S4. Changes in HSA fluorescence emission spectra upon addition of 1 (1-5 molar equivalents); 
T=298.0 K±0.1 °C, 30mM PBS, pH=7.35. 
 
 
Figure S5. The Stern-Volmer plot for binding of 1 to HSA. y = 1 + 113185.8 x. 
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Ksv=(1.13±0.04)×10
5 M-1   
 
Compound 2  
 
AGP: 
 
 
Figure S6. Changes in AGP fluorescence emission spectra upon addition of 2 (1-10 molar equivalents); 
T=298.0 K±0.1 °C, 30 mM PBS, pH=7.42. 
 
 
Figure S7. The Stern-Volmer plot for binding of 2 to AGP. y = 1 + 61187.3 x. 
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Figure S8. Changes in HSA fluorescence emission spectra upon addition of 2 (1-10 molar equivalents); 
T=298.0 K±0.1 °C, 30mM PBS, pH=7.42. 
 
 
Figure S9. The Stern-Volmer plot for binding of 2 to HSA. y = 1 + 88495.3 x. 
 
Ksv=(8.85±0.30)×10
4 M-1   
 
5. In vivo Mouse Pharmacokinetics.  
 
Compound 2 was dissolved in water and administered intraperitoneally at 20 mg/kg/day dose for 7 
consecutive days. Blood was collected from 3 mice, previously anaesthetized with chloroform, 24 hours 
after the last dose, via cardiac puncture. Samples were immediately centrifuged and serum stored at -20 
°C until the moment of analysis. Human serum was collected from a healthy volunteer and stored in 
refrigerator at 4 °C. Total concentrations of compound in mice samples were determined by 
precipitation of proteins by addition of two volume equivalents of acetonitrile (50 μL of sample and 100 
μL of acetonitrile), following 15 seconds on vortex and 30 min in ultrasound bath. After centrifugation of 
denatured proteins (10 minutes, 13400 rpm), supernatants were injected. Calibration curves were 
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prepared using blank human serum. Compound standard solutions were prepared in water. Human 
serum was spiked with stock solutions; final solutions were incubated at 37 °C for 1 h and treated with 
acetonitrile in the same manner. Concentrations of compound in mice serum were quantitated using a 
Waters Acquity UPLC H-Class (WAT-176015007) (Milford, MA,USA) with Poroshell 120 EC-C18 column 
(4.6 × 50mm, 2.7µ, S.N. USCFU07797) and interfaced to mass detector (Waters TQ (Tandem 
Quadrupole, WAT-176001263)). Single ion recording experiment (SIR) was used, by monitoring ions: 
[M+H]1+ (515), for the compound, and [M+2]+, [M+16]+, [M+32]+, [M-2]+, [M+14]+, [M+30]+, [M+18]+, 
[M+34]+ for the possible metabolites.8 Column temperature was maintained at 40 °C and mobile phase 
flow rate at 0.3 mL/min. The mobile phase consisted of ultrapure water (TKA Germany MicroPure water 
purification system, 0.055 μS/cm) containing 0.2 vol.% formic acid (solvent A) and acetonitrile (solvent 
B). For detection of total concentration, limit of detection (LOD) was 0.08 ppm (S/N = 3:1), limit of 
quantitation (LOQ) was 0.17 ppm (S/N = 6:1) and R2=0.9939 (calibration curve was performed in 
triplicate).  
 
Table S3. Data for the calibration curve for 2. 
 
Salt concentration, ppm Base concentration, ppm Area 
0.1 0.08 746 
0.22 0.17 2387 
0.25 0.19 2707 
0.5 0.39 3354 
0.75 0.58 4157 
1.0 0.78 5400 
1.5 1.17 7164 
5.0 3.90 29409 
 
 
Figure S10. The calibration curve for 2. 
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Figure S11. Limit of detection and limit of quantification for 2 (ZSML08). 
 
Pursuit of possible 2 metabolites chromatograms (designation in the upper right corner of each 
chromatogram): 
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Figure S12. Possible 2 (ZSML08) metabolites chromatograms. 
 
A similar small study was performed for our previously published 1 compound. The dose used was 10 
mg/kg. A greater number of samples were collected, on the fifth and on the seventh day of the 
experiment, at given times after a dose was administered. Therefore, not all chromatograms will be 
presented. Instead only a representative one will. 1 was present at concentrations between 0.46 and 
1.03 µM. 
 
Table S4. Concentration of 1 in different mice.  
Day Sample Area Concentration, µM  
5th 15 min, mouse 1 684 1.03 
5th 15 min, mouse 2 <LOD <LOD 
5th 30 min, mouse 1 <LOD <LOD 
5th 30 min, mouse 2 480 0.70 
5th 45 min, mouse 1 <LOD <LOD 
5th 45 min, mouse 2 <LOD <LOD 
5th 90 min, mouse 1 386 0.55 
5th 90 min, mouse 2 340 0.48 
5th 180 min, mouse 1 425 0.61 
5th 180 min, mouse 2 329 0.46 
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7th 5 min, mouse 1 <LOD <LOD 
7th 5 min, mouse 2 <LOD <LOD 
7th 20 min, mouse 1 <LOD <LOD 
7th 20 min, mouse 2 <LOD <LOD 
7th 60 min, mouse 1 415 0.60 
7th 60 min, mouse 2 <LOD <LOD 
7th 120 min, mouse 1 449 0.65 
7th 120 min, mouse 2 <LOD <LOD 
7th 240 min, mouse 1 <LOD <LOD 
7th 240 min, mouse 2 327 0.46 
 
 
Figure S13. Chromatographs for a sample taken on the 5th day, 15 minutes after the dose, from one 
mouse: From top down: original chromatogram; spiking the sample with 1 (ZS48) to identify the correct 
peak. 
 
 
The concentrations were calculated on the basis of the calibration curve: 
 
Table S5. Data for the calibration curve for 1. 
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Salt concentration, ppm Base concentration, ppm Area 
0.1 0.08 - 
0.2 0.15 234 
0.5 0.39 530 
0.7 0.54 679 
1.0 0.77 1025 
1.5 1.16 1562 
2.0 1.54 2160 
3.0 2.31 2980 
4.0 3.09 4004 
5.0 3.86 - 
  
  
 
Figure S14. The calibration curve for 1. 
 
 
The limit of detection (LOD) limit of quantification (LOQ) were below 0.08 ppm (1/15 signal/noise at that 
concentration).  
 
Note: “ZSML008” which appears on certain chromatographs here and in the paper is a mistake by the 
operator who accidentally typed that instead of “ZSML08”. 
“TIC (ZS48)” which appears on certain chromatographs here and in the paper refers to the total ion 
current and other mass spectrometry parameters set up for the method used for ZS48, and the same 
MS method was used for ZSML08 as well. 
 
6.  pKa determination. 
 
The compounds were dissolved in 25.00 mL 0.1 M NaCl in MeOH:H2O = 1:1 (v:v). Each solution was 
titrated with 0.0764 M NaOH (MeOH:H2O = 1:1, v:v), increment volume 2.0 µL. The titrations were 
performed in an Ar atmosphere at T=25±1ºC; 
Software package HYPERQUAD2008 was used to interpret data.9 
y = 1291.6x + 39.373 
R² = 0.9981 
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Aparatus: Potentiometric titrations were performed using CRISON pH-Burette 24 2S equipped with 
CRISON 50 29 micro-combined pH electrode (CRISON INSTRUMENTS, S.A. Spain). The electrode was 
calibrated by means of a strong acid – strong base titration in 0.1 M NaCl in MeOH:H2O (1:1, v:v), using 
GLEE – GLass Electrode Evaluation software;10 standard potential E0=386.1±0.6 mV, slope 58.4±0.3 mV, 
and pKW 13.78±0.01 values are obtained as mean values of five (2) or three (4, 13) titrations. 
 
2 (ZSML08): 
CZSML08 = 5.7514  10
-4 M (0.1 M NaCl in MeOH:H2O = 1:1)  
 
Table S6. 2 titration data.  
 
experiment pKa1 pKa2 pKa3 ± SD pKa4 ± SD pKa5 ± SD pKa6 ± SD 
1 
p
K
a 
o
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t 
o
f 
ti
tr
at
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p
K
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f 
ti
tr
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an
ge
 4.56 ± 0.01 5.49± 0.01 6.56± 0.01 7.64± 0.01 
2 4.66 ± 0.01 5.64± 0.01 6.65± 0.01 7.78± 0.01 
3 4.46 ± 0.01 5.62± 0.02 6.60± 0.01 7.71± 0.01 
4 4.97 ± 0.08 5.59± 0.08 6.68± 0.06 7.60± 0.08 
5 4.83 ± 0.05 5.64± 0.04 6.77± 0.05 7.79± 0.06 
<pKa>   4.56 ± 0.08 5.60 ± 0.06 6.65 ± 0.07 7.70 ± 0.07 
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Figure S15. 2 titration data. 
 
13 (ZS102): 
 
Table S7. 13 titration data.  
 
CZS102 = 6.829  10
-4 M  
  
experiment pKa1 pKa2 pKa3 pKa4 ± SD pKa5 ± SD pKa6 ± SD 
1 pK a
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g e 5.49 ± 0.05 8.51 ± 0.06 10.96 ± 0.06 
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2 5.48 ± 0.05 8.50 ± 0.06 11.08 ± 0.06 
3 5.57 ± 0.06 8.50 ± 0.03 10.87 ± 0.03 
<pKa>    5.51 ± 0.06 8.50 ± 0.01 10.97 ± 0.11 
 
N
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N
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Figure S16. 13 titration data.  
 
 
4 (ZS103): 
 
Table S8. 4 titration data.  
 
CZS103 = 4.608  10
-4 M  
 
experiment pKa1 pKa2 pKa3 pKa4 ± SD pKa5 ± SD pKa6 ± SD 
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 5.85 ± 0.08 8.69 ± 0.07 10.69 ± 0.04 
2 5.74 ± 0.08 8.65 ± 0.08 10.80 ± 0.04 
3 5.73 ± 0.09 8.61 ± 0.07 10.74 ± 0.06 
<pKa>    5.77 ± 0.07 8.65 ± 0.04 10.74 ± 0.06 
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Figure S17. 4 titration data.  
 
 
1 (ZS48): 
 
Table S9. 1: titration data.  
 
CZS48 = 3.099  10
-4 M (0.1 M NaCl u MeOH:H2O = 1:1)  
 
experiment pKa1 pKa2 pKa3 ± SD pKa4 ± SD pKa5 ± SD pKa6 ± SD 
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 4.37 ± 0.01 5.26 ± 0.01 5.97 ± 0.01 7.41 ± 0.01 
2 4.60 ± 0.01 5.17 ± 0.01 6.02 ± 0.01 7.36 ± 0.01 
3 4.39 ± 0.01 5.25 ± 0.01 5.94 ± 0.01 7.33 ± 0.01 
4 4.34 ± 0.01 5.26 ± 0.01 5.91 ± 0.01 7.31 ± 0.01 
<pKa>   4.37 ± 0.03 5.24 ± 0.04 5.96 ± 0.05 7.35 ± 0.04 
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Figure S18. 1 titration data.  
 
 
Chloroquine: 
 
Table S10. Chloroquine titration data.  
 
 
 
 
experiment pKa1±SD pKa2±SD 
NCl
NH
N pK
pK  
1. 7.42±0.01 9.08±0.01 
2. 7.49±0.01 9.24±0.01 
3. 7.46±0.01 9.18±0.01 
4. 7.44±0.01 9.20±0.01 
c=1.024∙10-3 M <pKa> 7.45±0.01 9.18±0.01 
 
pKa values were assigned based on calculations11,12: 
 
1: 
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2: 
 
 
4: 
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13: 
 
Order of protonation: 
 
Considering the basicity of N atom from the side chains (the morpholine N in 1 and 2 vs. –NEt2 in 4 and 
13) and the size of the aromatic systems, it is expected that aromatic N gets protonated first within 1 
and 2 (morpholine N in the second step), but not within 4 and 13, where much higher basicity of –NEt2 
dictates it’s protonation as the first step. This is due to the oxygen electron withdrawing effects of the 
morpholine side chain which lowers the basicity of N comparing to –NEt2 but also due to positive charge 
delocalization within the aromatic system. The effect of system stabilization due to positive charge 
delocalization is much more pronounced within 1 and 2 comparing to 4 and 13 as the size of the 
aromatic system is doubled. 
 
The ADMET Predictor software confirmed the proposed protonation order.9,10  
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7. Zebrafish model toxicity assessment. 
 
Evaluation of toxicity of 2 (ZSML08), 1 (ZS48) and CQ on the zebrafish embryos model was carried out 
according to general rules of the OECD Guidelines for the Testing of Chemicals.13 All experiments 
involving zebrafish were performed in compliance with the European directive 2010/63/EU and the 
ethical guidelines of the Guide for Care and Use of Laboratory Animals of the Institute of Molecular 
Genetics and Genetic Engineering, University of Belgrade. 
Wild type zebrafish (Danio rerio) were kindly provided by Dr Ana Cvejic (Wellcome Trust Sanger 
Institute, Cambridge, UK), housed in a temperature- and light-controlled facility under 28 °C and 
standard 14:10-hour light-dark photoperiod, and regularly fed with commercial dry flake food 
(TetraMinTM flakes; Tetra Melle, Germany) twice a day and Artemia nauplii once daily. Zebrafish 
embryos were produced by pair-wise mating, collected and distributed into 24-well plates containing 10 
embryos per well and 1 mL embryos water (0.2 g/L of Instant Ocean® Salt in distilled water), and raised 
at 28 °C. For assessing lethal and developmental toxicity, embryos at the 6 hours post fertilization (hpf) 
stage were treated with seven concentrations (2.5, 5, 10, 20, 30, 40 and 50 µM) of 2 (ZSML08), 1 (ZS48) 
and CQ. DMSO (0.1%) was used as negative control. Experiments were performed three times using 40 
embryos per concentration.  
Apical endpoints for the toxicity evaluation (Table S11) were recorded at 24, 48, 72, 96 and 120 
hpf using an inverted microscope (CKX41; Olympus, Tokyo, Japan). Dead embryos were counted and 
discarded every 24 h. At 120 hpf, embryos were inspected for heartbeat rate, anesthetized by addition 
of 0.1% (w/v) tricaine solution (Sigma-Aldrich, St. Louis, MO), photographed and killed by freezing at -
20°C for ≥ 24 h. None of the lethal and teratogenic effects (listed in table S11) were registered.  
Toxicity was evaluated by determination of the lethal concentration (LC50), defined as the 
treatment concentration resulting in the 50% mortality of embryos over a period of 120 hpf. The LC50 
value was determined by the program ToxRatPro (ToxRat®, Software for the Statistical Analysis of 
Biotests, ToxRat Solution GmbH, Alsdorf, Germany, Version 2.10.05) using probit analysis with linear 
maximum likelihood regression. 
In order to analyze compound 1 and 2 for possible hepatotoxic effect in vivo, the transgenic Tg(l-
fabp:EGFP) zebrafish embryos with the fluorescently labeled liver were treated with tested compounds 
at 6 hpf when the liver has not yet been formed (assessing the effect on the liver development), and at 
72 hpf when the liver is fully functional (assessing the effect on the liver function). Embryos were 
treated with the doses of 1 and 2 in the range of 10 to 40 μM, and of CQ in the range of 10 to 100 µM. 
Experiments were performed three times using 6 embryos per concentration. The hepatotoxicity was 
determined according to the change of liver area index compared to the control group, calculated as the 
ration between liver area and embryonic lateral area x 100%, as reported by Zhang et al (2017).14  
In order to analyze antiviral 1 and 2 for possible myelotoxicity in vivo, its effect on neutrophil 
occurrence in transgenic Tg(mpx:EGFP) zebrafish embryos with fluorescently labeled neutrophils was 
explored, enabling direct visualization of applied treatment on the neutrophils. Embryos staged at 6 hpf 
were treated with the doses of 1 and 2 in the range of 10 to 40 μM, and after 72-h treatment 
neutrophils were imaged using fluorescence microscope (Olympus BX51, Applied Imaging Corp., San 
Jose, CA, USA). Experiments were performed two times using 20 embryos per concentration.  
All mentioned measurements were performed by using Image J program (National Institutes of 
Health, USA). 
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Figure S19. The dose-response survival curve of zebrafish embryos at 120 hpf upon antiviral 2 (ZSML08), 
1 (ZS48) and CQ treatments.  
 
Figure S20. The hepatotoxicity of 2 (ZSML08), 1 (ZS48) and CQ evaluated in Tg(l-fabp:EGFP) zebrafish 
embryos with fluorescently labeled the liver. A. In vivo imaging of the liver morphology of 120-h old 
embryos exposed to tested compounds at 6 hpf and 
 
Table S11. Lethal and teratogenic effects inspected in zebrafish (Danio rerio) embryos upon 2 (ZSML08), 
1 (ZS48) and CQ treatments at different hours post fertilization (hpf). 
Category   Developmental endpoints  Exposure time (hpf) 
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    24  48  72  96/120 
        Lethal effect  Egg coagulationa  ● ● ● ● 
  No somite formation  ● ● ● ● 
  Tail not detached  ● ● ● ● 
  No heartbeat   ● ● ● 
        
Teratogenic effect  Malformation of head  ● ● ● ● 
  Malformation of eyes
b
  ● ● ● ● 
  Malformation of sacculi/otoliths
c
  ● ● ● ● 
  Malformation of notochord  ● ● ● ● 
  Malformation of tail
d
  ● ● ● ● 
  Scoliosis  ● ● ● ● 
  Heartbeat frequency   ● ● ● 
  Blood circulation   ● ● ● 
  Pericardial edema  ● ● ● ● 
  Yolk edema  ● ● ● ● 
  Liver morphology and color    ● ● 
  Yolk absosrption  ● ● ● ● 
  Growth retardation
e
  ● ● ● ● 
aNo clear organs structure is recognized. 
bMalformation of eyes was recorded for the retardation in eye development and abnormality in shape 
and size. 
cPresence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of 
otoliths and/or sacculi (otic vesicles). 
dTail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as 
assessed by optical comparation. 
eGrowth retardation was recorded by comparing with the control embryos in development or size 
(before hatching, at 24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using 
by optical comparation using a inverted microscope (CKX41; Olympus, Tokyo, Japan). 
 
8. Tolerability assay in mice 
Groups of six healthy female C57Bl/6 mice were once daily treated intraperitoneally with a dose of the 
compound dissolved in 0.9% aqueous NaCl, for 7 days. Individual mouse behavior and appearance was 
monitored two times a day for 28 days after the last dose. Compounds proved to be non-toxic if all mice 
survived 28 days after administration and showed normal appearance and behavior. The study followed 
the International Guiding Principles for biomedical research involving animals, and was reviewed by a 
local Ethics Committee and approved by the Veterinary Directorate at the Ministry of Agriculture and 
Environmental Protection of Serbia (decision no. 323-07-02444/2014-05/1). 
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